COL7A1 and recessive dystrophic epidermolysis bullosa: The COL7A1 frame restoration efficiency was further improved via non-homologous end-joining (NHEJ) using CRISPR-Cas9 ribonucleoprotein that was electroporated into primary RDEB patient keratinocytes (RDEBK) as ex vivo treatment.33